
    
      The study will assess real-world evidence data of anticoagulation and antiplatelet therapy in
      patients with NVAF undergoing PCI treated with edoxaban. The observation period will start 4
      to 72 hours after removal of the guiding catheter of successful PCI in a hospital and ends 1
      year after procedure. Follow-up telephone calls will take place approximately 1 month and 1
      year after PCI. Real-world data of effectiveness of edoxaban and antiplatelet therapy,
      clinical events of interests, safety and quality of life (QoL) data of edoxaban will be
      collected.
    
  